| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,395,152 | 16 | 100 |
| Cioffi Melina | SVP, Regulatory Affairs | 0 | $0 | 1 | $105,623 | $-105,623 |
| Korczynski Sherry | Chief Commercial Officer | 0 | $0 | 2 | $111,362 | $-111,362 |
| Boyd Peter E. | Chief People Officer | 0 | $0 | 1 | $124,414 | $-124,414 |
| Krop Julie | director | 0 | $0 | 1 | $125,393 | $-125,393 |
| BRAENDER LORI J | Chief Legal Officer | 0 | $0 | 1 | $167,346 | $-167,346 |
| Jung Cassie | Chief Operating Officer | 0 | $0 | 1 | $191,086 | $-191,086 |
| TOTH A ERNEST JR | Chief Financial Officer | 0 | $0 | 1 | $243,094 | $-243,094 |
| Barber Daniel | President and CEO | 0 | $0 | 8 | $1.33M | $-1.33M |
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage …
Over the last 12 months, insiders at Aquestive Therapeutics, Inc. have bought $0 and sold $2.4M worth of Aquestive Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aquestive Therapeutics, Inc. have bought $63,498 and sold $1.51M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $4,050 was made by Boyd Peter E. (SVP‑Bus. Process & Info. Tech.) on 2022‑06‑14.
| 2026-10-15 | Sale | Barber Daniel | President and CEO | 25,000 0.0207% | $4.22 | $105,600 | -1.48% | |
| 2026-09-15 | Sale | Barber Daniel | President and CEO | 25,000 0.02% | $4.82 | $120,488 | -4.16% | |
| 2026-09-09 | Sale | Korczynski Sherry | Chief Commercial Officer | 8,750 0.0071% | $5.22 | $45,675 | -10.49% | |
| 2026-08-17 | Sale | Barber Daniel | President and CEO | 25,000 0.02% | $4.29 | $107,168 | +8.86% | |
| 2026-07-16 | Sale | Barber Daniel | President and CEO | 20,369 0.0208% | $4.00 | $81,509 | +14.21% | |
| 2026-07-15 | Sale | Barber Daniel | President and CEO | 4,631 0.0048% | $4.03 | $18,683 | +13.16% | |
| 2026-06-23 | Sale | Krop Julie | director | 25,000 0.0251% | $5.02 | $125,393 | -14.31% | |
| 2026-06-15 | Sale | Barber Daniel | President and CEO | 25,000 0.0248% | $4.16 | $104,010 | +2.49% | |
| 2026-05-15 | Sale | Barber Daniel | President and CEO | 8,257 0.0086% | $4.29 | $35,413 | +1.56% | |
| 2026-03-10 | Sale | Barber Daniel | President and CEO | 180,677 0.177% | $4.17 | $753,965 | -0.48% | |
| 2026-03-10 | Sale | BRAENDER LORI J | Chief Legal Officer | 40,102 0.0393% | $4.17 | $167,346 | -0.48% | |
| 2026-03-10 | Sale | TOTH A ERNEST JR | Chief Financial Officer | 58,254 0.0571% | $4.17 | $243,094 | -0.48% | |
| 2026-03-10 | Sale | Boyd Peter E. | Chief People Officer | 29,814 0.0292% | $4.17 | $124,414 | -0.48% | |
| 2026-03-10 | Sale | Jung Cassie | Chief Operating Officer | 45,791 0.0449% | $4.17 | $191,086 | -0.48% | |
| 2026-03-10 | Sale | Cioffi Melina | SVP, Regulatory Affairs | 25,311 0.0248% | $4.17 | $105,623 | -0.48% | |
| 2026-03-10 | Sale | Korczynski Sherry | Chief Commercial Officer | 15,741 0.0154% | $4.17 | $65,687 | -0.48% | |
| 2025-10-15 | Sale | Kraus Carl N | Chief Medical Officer | 20,272 0.0194% | $7.00 | $141,904 | -42.23% | |
| 2025-10-15 | Sale | Boyd Peter E. | See Remarks | 10,000 0.0096% | $7.00 | $70,000 | -42.23% | |
| 2025-10-15 | Sale | Jung Cassie | Chief Operating Officer | 67,575 0.0647% | $7.01 | $473,701 | -42.23% | |
| 2025-09-26 | Sale | Barber Daniel | President and CEO | 91,343 0.0923% | $6.03 | $551,191 | -29.22% |
| Barber Daniel | President and CEO | 627317 0.4998% | $2.43M | 2 | 10 | <0.0001% |
| BRAENDER LORI J | Chief Legal Officer | 442879 0.3529% | $1.72M | 4 | 1 | +53.97% |
| Boyd Peter E. | Chief People Officer | 338509 0.2697% | $1.31M | 5 | 4 | +43.71% |
| Schobel Alexander Mark | Chief Innovation/Tech Officer | 984476 0.7844% | $3.82M | 4 | 9 | <0.0001% |
| Kendall Keith J | 638964 0.5091% | $2.48M | 6 | 1 | <0.0001% | |
| BRATTON DOUGLAS K | 165000 0.1315% | $640,200.00 | 1 | 0 | <0.0001% | |
| Maxwell John T. | 150614 0.12% | $584,382.32 | 2 | 1 | <0.0001% | |
| Wood Theresa | 80765 0.0643% | $313,368.20 | 2 | 0 | <0.0001% | |
| Scibetta James S | 31635 0.0252% | $122,743.80 | 3 | 0 | +13.42% | |
| Marshall Ken W. | 1445 0.0012% | $5,606.60 | 1 | 0 | <0.0001% |
$14,599,168 | 59 | 12.79% | $1.66B | |
$102,709,455 | 46 | 30.55% | $1.45B | |
$33,884,330 | 45 | 12.56% | $223.45M | |
$98,035,963 | 43 | -10.97% | $486.79M | |
$11,542,910 | 40 | 56.19% | $1.07B |
| Increased Positions | 113 | +77.4% | 15M | +22.43% |
| Decreased Positions | 61 | -41.78% | 9M | -13.21% |
| New Positions | 45 | New | 4M | New |
| Sold Out Positions | 23 | Sold Out | 2M | Sold Out |
| Total Postitions | 198 | +35.62% | 72M | +9.22% |
| Bratton Capital Management, L.P. | $63,281.00 | 8.04% | 9.81M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $42,091.00 | 5.35% | 6.53M | +49,077 | +0.76% | 2025-09-30 |
| Rtw Investments, Lp | $40,313.00 | 5.12% | 6.25M | +6M | New | 2025-09-30 |
| Vanguard Group Inc | $36,521.00 | 4.64% | 5.66M | +1M | +30.81% | 2025-09-30 |
| Perceptive Advisors Llc | $24,253.00 | 3.08% | 3.76M | +2M | +71.66% | 2025-09-30 |
| Ecor1 Capital, Llc | $16,931.00 | 2.15% | 2.63M | +3M | New | 2025-09-30 |
| Samsara Biocapital, Llc | $16,125.00 | 2.05% | 2.5M | +3M | New | 2025-09-30 |
| Geode Capital Management, Llc | $13,467.00 | 1.71% | 2.09M | +110,947 | +5.61% | 2025-09-30 |
| State Street Corp | $10,334.00 | 1.31% | 1.6M | +94,918 | +6.3% | 2025-09-30 |
| Sio Capital Management, Llc | $9,663.00 | 1.23% | 1.5M | +550,606 | +58.11% | 2025-09-30 |